WO2013082563A8 - Protein inhibitors to complement and vegf pathways and methods of use thereof - Google Patents

Protein inhibitors to complement and vegf pathways and methods of use thereof Download PDF

Info

Publication number
WO2013082563A8
WO2013082563A8 PCT/US2012/067489 US2012067489W WO2013082563A8 WO 2013082563 A8 WO2013082563 A8 WO 2013082563A8 US 2012067489 W US2012067489 W US 2012067489W WO 2013082563 A8 WO2013082563 A8 WO 2013082563A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
complement
protein inhibitors
vegf pathways
vegf
Prior art date
Application number
PCT/US2012/067489
Other languages
French (fr)
Other versions
WO2013082563A1 (en
Inventor
Jeng-Horng Her
Huang-Tsu Chen
Original Assignee
Protevobio, Inc.
Innovent Biologics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES12853600.0T priority Critical patent/ES2651521T3/en
Priority to CN201280068781.7A priority patent/CN104159926B/en
Priority to US14/362,109 priority patent/US9988611B2/en
Priority to CA2857168A priority patent/CA2857168C/en
Priority to JP2014544968A priority patent/JP6138815B2/en
Priority to BR112014013205-4A priority patent/BR112014013205A2/en
Application filed by Protevobio, Inc., Innovent Biologics, Inc. filed Critical Protevobio, Inc.
Priority to EP12853600.0A priority patent/EP2785744B1/en
Priority to DK12853600.0T priority patent/DK2785744T3/en
Priority to AU2012318288A priority patent/AU2012318288B2/en
Publication of WO2013082563A1 publication Critical patent/WO2013082563A1/en
Publication of WO2013082563A8 publication Critical patent/WO2013082563A8/en
Priority to US15/965,382 priority patent/US11518984B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01112—Protein-tyrosine kinase (2.7.1.112)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

The invention provides bispecific fusion proteins that inhibit activation of complement pathway and vascular endothelial growth factor (VEGF) pathway and methods for using these fusion proteins.
PCT/US2012/067489 2011-12-01 2012-11-30 Protein inhibitors to complement and vegf pathways and methods of use thereof WO2013082563A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN201280068781.7A CN104159926B (en) 2011-12-01 2012-11-30 The protein inhibitor and its application method of complement and VEGF pathway
US14/362,109 US9988611B2 (en) 2011-12-01 2012-11-30 Protein inhibitors to complement and VEGF pathways and methods of use thereof
CA2857168A CA2857168C (en) 2011-12-01 2012-11-30 Protein inhibitors to complement and vegf pathways and methods of use thereof
JP2014544968A JP6138815B2 (en) 2011-12-01 2012-11-30 Protein inhibitors for the complement and VEGF pathways and methods for their use
BR112014013205-4A BR112014013205A2 (en) 2011-12-01 2012-11-30 fusion protein, its use and production method, pharmaceutical composition, nucleic acid, and kit
ES12853600.0T ES2651521T3 (en) 2011-12-01 2012-11-30 Protein inhibitors of complement and VEGF pathways and methods of use thereof
EP12853600.0A EP2785744B1 (en) 2011-12-01 2012-11-30 Protein inhibitors to complement and vegf pathways and methods of use thereof
DK12853600.0T DK2785744T3 (en) 2011-12-01 2012-11-30 PROTEIN INHIBITORS FOR COMPLEMENT AND VEGF PATHWAYS AND PROCEDURES FOR USE THEREOF
AU2012318288A AU2012318288B2 (en) 2011-12-01 2012-11-30 Protein inhibitors to complement and VEGF pathways and methods of use thereof
US15/965,382 US11518984B2 (en) 2011-12-01 2018-04-27 Protein inhibitors to complement and VEGF pathways and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161629932P 2011-12-01 2011-12-01
US61/629,932 2011-12-01

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/362,109 A-371-Of-International US9988611B2 (en) 2011-12-01 2012-11-30 Protein inhibitors to complement and VEGF pathways and methods of use thereof
US15/965,382 Division US11518984B2 (en) 2011-12-01 2018-04-27 Protein inhibitors to complement and VEGF pathways and methods of use thereof

Publications (2)

Publication Number Publication Date
WO2013082563A1 WO2013082563A1 (en) 2013-06-06
WO2013082563A8 true WO2013082563A8 (en) 2014-06-26

Family

ID=48536152

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/067489 WO2013082563A1 (en) 2011-12-01 2012-11-30 Protein inhibitors to complement and vegf pathways and methods of use thereof

Country Status (10)

Country Link
US (2) US9988611B2 (en)
EP (1) EP2785744B1 (en)
JP (2) JP6138815B2 (en)
CN (2) CN110078831A (en)
AU (1) AU2012318288B2 (en)
BR (1) BR112014013205A2 (en)
CA (1) CA2857168C (en)
DK (1) DK2785744T3 (en)
ES (1) ES2651521T3 (en)
WO (1) WO2013082563A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2857168C (en) 2011-12-01 2020-10-27 Protevobio, Inc. Protein inhibitors to complement and vegf pathways and methods of use thereof
CN104721820A (en) * 2013-12-24 2015-06-24 信达生物制药(苏州)有限公司 Application of bispecific monoclonal antibody to treatment of uveitis
US9856310B2 (en) * 2014-02-24 2018-01-02 Takeda Pharmaceutical Company Limited UTI fusion proteins
JP6355032B2 (en) * 2014-03-24 2018-07-11 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド Novel recombinant bifunctional fusion proteins, their preparation and use
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN105327346B (en) * 2014-08-07 2019-10-18 信达生物制药(苏州)有限公司 A kind of application of monoclonal antibody in treatment psoriasis
CN105435222B (en) * 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 Recombination fusion protein preparation
CN104940926B (en) * 2014-09-25 2017-09-22 信达生物制药(苏州)有限公司 Recombination fusion protein preparation
CN106084062B (en) * 2015-04-28 2021-04-02 荣昌生物制药（烟台）有限公司 Bridged bispecific fusion proteins
WO2017001990A1 (en) * 2015-06-28 2017-01-05 Allgenesis Biotherapeutics Inc. Fusion proteins for inhibiting angiogenesis
EP3377101A4 (en) * 2015-11-19 2019-08-07 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
CN106890313A (en) * 2015-12-18 2017-06-27 信达生物制药(苏州)有限公司 Medicine for treating pathological myopia
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2017114401A1 (en) * 2015-12-31 2017-07-06 江苏匡亚生物医药科技有限公司 Recombinant complement factor h-immunoglobulin fusion protein with complement regulating activity, and preparation method therefor and use thereof
KR101685532B1 (en) * 2016-04-26 2016-12-13 한국프라임제약주식회사 A VEGFR fusion protein
EA037848B1 (en) * 2016-07-14 2021-05-27 Общество С Ограниченной Ответственностью "Биохимический Агент" Fusion protein, polynucleotide, genetic construct, producer, preparation for regeneration of cartilage (variants)
AU2018265258B2 (en) * 2017-05-10 2023-01-05 Pharma Cinq, Llc Enveloped virus resistant to complement inactivation for the treatment of cancer
CN107602702A (en) * 2017-09-22 2018-01-19 生标（上海）医疗器械科技有限公司 Antibody that is a kind of while targetting people p185 and VEGF and its application
GB201800620D0 (en) * 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
AU2019227997A1 (en) 2018-03-02 2020-09-24 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
PT3793586T (en) * 2018-05-16 2024-07-10 Csl Ltd Soluble complement receptor type 1 variants and uses thereof
JP7249060B2 (en) * 2018-08-17 2023-03-30 トリカン・バイオテクノロジー・カンパニー・リミテッド Antiangiogenic fusion proteins and uses thereof
US20200115443A1 (en) * 2018-10-12 2020-04-16 Trican Biotechnology Co., Ltd Bi-functional fusion proteins and uses thereof
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CN111378044B (en) * 2018-12-28 2022-07-15 长春金赛药业有限责任公司 Antibody fusion protein, preparation method and application thereof
CN111423512B (en) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 Multi-targeting fusion protein for blocking vascular endothelial cell growth and activating T cells and pharmaceutical composition comprising same
JP7444968B2 (en) * 2019-04-13 2024-03-06 ナショナル・センター・フォー・セル・サイエンス DAF-MCP chimeric protein, method for its production and use of the chimeric protein to treat pathological conditions involving the complement system
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN118750581A (en) * 2019-12-24 2024-10-11 信达生物制药(苏州)有限公司 Use of fusion proteins in the treatment of age-related macular degeneration
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
JP7560185B2 (en) 2020-07-07 2024-10-02 カナプ セラピューティクス インコーポレイテッド Fusion proteins comprising complement pathway inhibitors and angiogenesis inhibitors and uses thereof
CN113041360A (en) * 2021-04-01 2021-06-29 深圳廷美奥生物技术有限公司 Medicine for treating age-related macular degeneration
EP4386009A1 (en) * 2021-08-09 2024-06-19 Yuanpu Biotechnology (Wuhan) Co., Ltd. Bispecific fusion polypeptide and application thereof
TW202328211A (en) * 2021-11-19 2023-07-16 圓祥生技股份有限公司 Bi-functional fusion proteins to complement pathways, pharmaceutical composition and use of treating or preventing a complement related disease thereof
KR20230105972A (en) * 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 ANTI-C3b ANTIBODY OR ANTI-C5 ANTIBODY CONJUGATED WITH ANGIOGENESIS INHIBITOR AND USE THEREOF
CN116675777A (en) * 2022-02-23 2023-09-01 苏州光度生物科技有限公司 Multispecific ligand binding molecules comprising complement inhibition domains and uses thereof
GB202203627D0 (en) 2022-03-16 2022-04-27 Univ Manchester Agents for treating complement-related disorders
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
WO2024114641A1 (en) * 2022-11-28 2024-06-06 Shenzhen Oculgen Biomedical Technology Co., Ltd C5/vegf bispecific binding molecules
WO2024146953A1 (en) 2023-01-05 2024-07-11 Complement Therapeutics Limited Agents and methods for treating complement diseases
CN117467025B (en) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 anti-VEGF and complement bifunctional fusion protein and application thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL89790A (en) * 1988-04-01 2002-05-23 Johns Hopking University Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (en) 1989-04-28 1991-08-30 Transgene Sa NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1995008343A1 (en) * 1993-09-24 1995-03-30 Washington University Modified truncated complement system regulators
JP3951062B2 (en) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド Expression of antibody fragments with cysteine present at least as a free thiol in E. coli for the production of bifunctional F (ab ') 2 antibodies
DE69329503T2 (en) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutic use of chimeric and labeled antibodies directed against a differentiation antigen, the expression of which is restricted to human B lymphocyte, for the treatment of B cell lymphoma
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
GB9614871D0 (en) * 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
DE60041159D1 (en) * 1999-06-08 2009-01-29 Regeneron Pharma VEGF receptor chimeras for the treatment of ocular diseases characterized by vascular permeability.
AU2001279024B2 (en) * 2000-08-01 2007-05-17 Amgen Inc. C3b/C4b complement receptor-like molecules and uses thereof
NZ527126A (en) * 2001-02-09 2007-04-27 Human Genome Sciences Inc An antibody that immunospecifically binds G-protein chemokine receptor (CCR5) polypeptide
CN100594037C (en) * 2002-11-15 2010-03-17 Musc研究发展基金会 Complement receptor 2 targeted complement modulators
CN1764471A (en) 2003-03-24 2006-04-26 塔普医药产品公司 Use of chemokine receptor agonists for stem cell transplantation
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
JP2009505989A (en) * 2005-08-15 2009-02-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Fas ligand activated by VEGF
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
CN101325963B (en) 2005-10-08 2016-01-27 博泰迪亚制药公司 For compstatin and its analog of eye disorders
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US20070093443A1 (en) * 2005-10-21 2007-04-26 Madison Edwin L Modified proteases that inhibit complement activation
EP2826788B1 (en) 2006-06-21 2017-12-13 MUSC Foundation for Research Development Targeting complement factor h for treatment of diseases by the use of cr2-fh molecules
CA2666843C (en) * 2006-10-20 2015-06-16 Celldex Therapeutics, Inc. Treatment of age-related macular degeneration and other diseases of the eye
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CN102317320A (en) * 2008-12-11 2012-01-11 韩国科学技术院 Fusion proteins capable of binding to VEGF-A and TNF-alpha
WO2010118360A1 (en) * 2009-04-09 2010-10-14 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Production of proteins using transposon-based vectors
CN102219859B (en) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 Fusion protein for antagonizing angiogenesis inducible factor and application thereof
CA2857168C (en) 2011-12-01 2020-10-27 Protevobio, Inc. Protein inhibitors to complement and vegf pathways and methods of use thereof

Also Published As

Publication number Publication date
WO2013082563A1 (en) 2013-06-06
US20150079084A1 (en) 2015-03-19
US11518984B2 (en) 2022-12-06
US9988611B2 (en) 2018-06-05
AU2012318288A1 (en) 2013-06-20
CN110078831A (en) 2019-08-02
CA2857168C (en) 2020-10-27
CN104159926A (en) 2014-11-19
EP2785744B1 (en) 2017-10-04
EP2785744A4 (en) 2015-07-22
CN104159926B (en) 2019-02-01
JP2015500811A (en) 2015-01-08
AU2012318288B2 (en) 2015-09-17
ES2651521T3 (en) 2018-01-26
JP6138815B2 (en) 2017-05-31
DK2785744T3 (en) 2017-11-27
JP2017189167A (en) 2017-10-19
CA2857168A1 (en) 2013-06-06
EP2785744A1 (en) 2014-10-08
US20180312819A1 (en) 2018-11-01
BR112014013205A2 (en) 2020-10-27

Similar Documents

Publication Publication Date Title
WO2013082563A8 (en) Protein inhibitors to complement and vegf pathways and methods of use thereof
HK1221426A1 (en) Antibody locker for the inactivation of protein drug
EP3409278B8 (en) Heterocyclic protein kinase inhibitors
CO6950481A2 (en) Protein kinase inhibitors
DK3604339T3 (en) THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND METHODS OF USING THE SAME
EA201791693A1 (en) HETERODIMERNY IMMUNOHLOBULINS
DK3321276T3 (en) Fusion proteins for the treatment of metabolic disorders
ZA201306855B (en) Protein kinase inhibitors
EP3327118A4 (en) Method for inducing vascular endothelial cells
IL254242A0 (en) Dual signaling protein (dsp) fusion proteins, and methods of using thereof for treating diseases
BR112014001977A2 (en) selective protein kinase inhibitors
AU2012202594A1 (en) Thrombin isolated from blood and blood fractions
EP2866823A4 (en) Ctla4 fusion proteins for the treatment of diabetes
EP3210997C0 (en) Agents and methods for the expression and secretion of peptides and proteins
WO2013055418A3 (en) Cross-protective arenavirus vaccines and their method of use
HK1212896A1 (en) Monoclonal antibodies against activated protein c (apc) c(apc)
EP3192813A4 (en) Humanized monoclonal antibody for inhibiting vascular endothelial lipase enzyme activity
EP3279325A4 (en) Nucleic acid aptamer capable of bonding to vascular endothelial growth factor receptor
WO2012095432A3 (en) Tlr3 binding agents
EP3268011A4 (en) Inhibitors of dek protein and related methods
EP3211090A4 (en) Method for predicting sensitivity to vascular endothelial growth factor receptor inhibitor
EP3509631A4 (en) In vitro propagation of babesia microti
SG10201807066UA (en) Peptides and methods of use
WO2012166659A3 (en) Anti-emr1 antibodies
CO6821937A2 (en) New indolinone protein kinase inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2012318288

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12853600

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2857168

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2014544968

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14362109

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2012853600

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014013205

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014013205

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140530